Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Double-blind, Randomized, Dose Finding Clinical Trial with an Open-label Run-in Part to Assess the Safety and Immunogenicity of an Inactivated, Adjuvanted Whole Zika Virus Vaccine Candidate (VLA1601) in Healthy Flavivirus-naïve Adults Aged 18 to 49 Years

Next Previous
Trial Profile

A Phase 1 Double-blind, Randomized, Dose Finding Clinical Trial with an Open-label Run-in Part to Assess the Safety and Immunogenicity of an Inactivated, Adjuvanted Whole Zika Virus Vaccine Candidate (VLA1601) in Healthy Flavivirus-naïve Adults Aged 18 to 49 Years

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 27 Nov 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs VLA-1601 (Primary) ; CpG 1018; Telratolimod
  • Indications Zika virus infection
  • Focus Adverse reactions
  • Sponsors Valneva

Most Recent Events

  • 04 Nov 2025 Results published in the Media Release
  • 12 Aug 2025 According to a Valneva media release, Sentinel recruitment and vaccinations have been completed and results from the trial are expected this year.
  • 06 Mar 2025 Planned End Date changed from 28 Dec 2026 to 27 Apr 2026.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top